BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 12161476)

  • 1. Prevention of growth deceleration after withdrawal of growth hormone therapy in idiopathic short stature.
    Lampit M; Hochberg Z
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3573-7. PubMed ID: 12161476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation.
    Kamp GA; Mul D; Waelkens JJ; Jansen M; Delemarre-van de Waal HA; Verhoeven-Wind L; Frölich M; Oostdijk W; Wit JM
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2969-75. PubMed ID: 11443153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years.
    de Zegher F; Du Caju MV; Heinrichs C; Maes M; De Schepper J; Craen M; Vanweser K; Malvaux P; Rosenfeld RG
    J Clin Endocrinol Metab; 1999 May; 84(5):1558-61. PubMed ID: 10323379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone.
    Pasquino AM; Pucarelli I; Roggini M; Segni M
    J Clin Endocrinol Metab; 2000 Feb; 85(2):619-22. PubMed ID: 10690865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human growth hormone treatment of short-stature children born small for gestational age: effect on muscle and adipose tissue mass during a 3-year treatment period and after 1 year's withdrawal.
    Leger J; Garel C; Fjellestad-Paulsen A; Hassan M; Czernichow P
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3512-6. PubMed ID: 9768656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy.
    Barreca A; Bozzola M; Cesarone A; Steenbergh PH; Holthuizen PE; Severi F; Giordano G; Minuto F
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3534-41. PubMed ID: 9768660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short children born small for gestational age and treated with growth hormone for three years have an important catch-down five years after discontinuation of treatment.
    Fjellestad-Paulsen A; Simon D; Czernichow P
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1234-9. PubMed ID: 15001616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GH dependence and GH withdrawal syndrome in GH treatment of short normal children: evidence from growth and cardiac output.
    Lampit M; Lorber A; Vilkas DL; Nave T; Hochberg Z
    Eur J Endocrinol; 1998 Apr; 138(4):401-7. PubMed ID: 9578507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 5-year prospective study of growth hormone (GH)-deficient children treated with GH before the age of 3 years. French Serono Study Group.
    Rappaport R; Mugnier E; Limoni C; Crosnier H; Czernichow P; Leger J; Limal JM; Rochiccioli P; Soskin S
    J Clin Endocrinol Metab; 1997 Feb; 82(2):452-6. PubMed ID: 9024235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
    Mauras N; Attie KM; Reiter EO; Saenger P; Baptista J
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years.
    de Zegher F; Albertsson-Wikland K; Wollmann HA; Chatelain P; Chaussain JL; Löfström A; Jonsson B; Rosenfeld RG
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2816-21. PubMed ID: 10946888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone (GH)-binding protein in prepubertal short children born small for gestational age: effects of growth hormone treatment. Swedish Study Group for Growth Hormone Treatment.
    Boguszewski M; Bjarnason R; Rosberg S; Carlsson LM; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1014-9. PubMed ID: 9100566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial.
    Sas T; de Waal W; Mulder P; Houdijk M; Jansen M; Reeser M; Hokken-Koelega A
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3064-70. PubMed ID: 10487666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome.
    Cotterill AM; McKenna WJ; Brady AF; Sharland M; Elsawi M; Yamada M; Camacho-Hübner C; Kelnar CJ; Dunger DB; Patton MA; Savage MO
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2291-7. PubMed ID: 8964866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study.
    Cohen P; Rogol AD; Howard CP; Bright GM; Kappelgaard AM; Rosenfeld RG;
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2480-6. PubMed ID: 17356043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth response to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in short children with various GH secretion capacities. Swedish Study Group for Growth Hormone Treatment.
    Kriström B; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2889-98. PubMed ID: 9284715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment with gonadotropin-releasing hormone analog and growth hormone in central precocious puberty.
    Pasquino AM; Municchi G; Pucarelli I; Segni M; Mancini MA; Troiani S
    J Clin Endocrinol Metab; 1996 Mar; 81(3):948-51. PubMed ID: 8772556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia.
    Quintos JB; Vogiatzi MG; Harbison MD; New MI
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1511-7. PubMed ID: 11297576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature.
    Kriström B; Aronson AS; Dahlgren J; Gustafsson J; Halldin M; Ivarsson SA; Nilsson NO; Svensson J; Tuvemo T; Albertsson-Wikland K
    J Clin Endocrinol Metab; 2009 Feb; 94(2):483-90. PubMed ID: 19001519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.